v3.26.1
Equity Incentive Plan - Summary of Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 2 Months Ended
Apr. 20, 2026
[1]
Jun. 30, 2026
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Number of Shares Outstanding, Ending Balance   6,641,885
Stock Options    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Number of Shares Outstanding, Beginning Balance [1]   6,641,885
Granted   1,383,690
Exercises   (440,896)
Forfeitures and cancellations   0
Number of Shares Outstanding, Ending Balance 6,641,885 7,584,679
Number of Shares Exercisable , Ending Balance   3,708,578
Weighted Average Exercise Price, Beginning Balance [1]   $ 6.81
Weighted Average Exercise Price, Granted   17.85
Weighted Average Exercise Price, Exercised   5.88
Weighted Average Exercise Price, Forfeitures and cancellations   0
Weighted Average Exercise Price, Ending Balance $ 6.81 8.88
Weighted Average Exercise Price, Exercisable Ending Balance   $ 7.02
Weighted-Average Remaining Contractual Term in years 7 years 1 month 20 days 7 years 6 months 18 days
Weighted average remaining contractual term, Exercisable   6 years 1 month 24 days
Aggregate Intrinsic Value, Outstanding $ 78,934 $ 85,742
Aggregate Intrinsic Value, Exercisable   $ 49,037
[1] As part of the Spin-Off, 6,641,885 substitute options were issued related to options from the AnaptysBio Equity Plan.